Scholarlink

Background <p>Mobile health (mHealth) interventions may improve HIV care in the context of healthcare professional shortages. Here, we evaluate the performance of four mHealth components implemented during the Viral Load Triggered ART Care in Lesotho (VITAL) cluster randomised trial. VITAL enrolled adults with HIV receiving antiretroviral therapy (ART) at rural nurse-led clinics in Lesotho, Southern Africa. This secondary analysis includes the nine intervention clinics where participants were offered the following tailored mHealth support: (1) short message services (SMS): viral load result communication, visit and adherence reminders; (2) adherence counselling by phone; (3) callback service; and (4) automated remote tuberculosis screening. The aim of the study was to assess the technical feasibility and uptake of four mHealth support options offered to people with HIV taking ART in Lesotho.</p> Results <p>Between 14 October 2020 and 7 August 2024, 376,168 SMS notifications were sent to 2,520 participants, with 288,886 (76.8%) successfully delivered messages. Among those, 277,061 (95.9%) were adherence reminders, 6,949 (2.4%) were clinic visit reminders, and 4,876 (1.7%) were viral load result notifications. Among 435 participants with viremia, 316 (72.6%) were successfully informed by SMS, 11 (2.5%) completed remote adherence counselling via phone. Of 129 nurse callback requests from 112 participants, most related to questions regarding the VITAL study trial 49 (37.9%) and questions about ART intake 48 (37.2%), followed by other medical issues such as COVID-19 or body pains 9 (7.0%). Of 1,654 automated tuberculosis symptom calls triggered to participants, 31 (1.9%) were answered. Among these, 11 (35.5%) reported tuberculosis symptoms.</p> Conclusions <p>Automated SMS notifications to communicate viral load results and provide reminders for ART adherence and clinic visits encountered high uptake and were technically successful. However, uptake of other phone-based services was low, and technical challenges hindered the implementation of automated remote tuberculosis symptom screening calls.</p> Trial registration <p>ClinicalTrials.gov: NCT04527874 (registered 31 August 2020).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Technical feasibility and uptake of tailored mobile health support for people with HIV in Lesotho

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月14日

查看全文
  • Malebanye D. Lerotholi,
  • Mathebe Kopo,
  • Mpho Kao,
  • Lipontso Motaboli,
  • Moleboheng Mokebe,
  • Ntoiseng Chejane,
  • Makobefo Chakela,
  • Bienvenu L. Nsakala,
  • Blaise Lukau,
  • Irene Ayakaka,
  • Morongoe Nyakane,
  • Tapiwa Tarumbiswa,
  • Adrienne E. Shapiro,
  • Mirko S. Winkler,
  • Niklaus D. Labhardt,
  • Nadine Tschumi

摘要

Background

Mobile health (mHealth) interventions may improve HIV care in the context of healthcare professional shortages. Here, we evaluate the performance of four mHealth components implemented during the Viral Load Triggered ART Care in Lesotho (VITAL) cluster randomised trial. VITAL enrolled adults with HIV receiving antiretroviral therapy (ART) at rural nurse-led clinics in Lesotho, Southern Africa. This secondary analysis includes the nine intervention clinics where participants were offered the following tailored mHealth support: (1) short message services (SMS): viral load result communication, visit and adherence reminders; (2) adherence counselling by phone; (3) callback service; and (4) automated remote tuberculosis screening. The aim of the study was to assess the technical feasibility and uptake of four mHealth support options offered to people with HIV taking ART in Lesotho.

Results

Between 14 October 2020 and 7 August 2024, 376,168 SMS notifications were sent to 2,520 participants, with 288,886 (76.8%) successfully delivered messages. Among those, 277,061 (95.9%) were adherence reminders, 6,949 (2.4%) were clinic visit reminders, and 4,876 (1.7%) were viral load result notifications. Among 435 participants with viremia, 316 (72.6%) were successfully informed by SMS, 11 (2.5%) completed remote adherence counselling via phone. Of 129 nurse callback requests from 112 participants, most related to questions regarding the VITAL study trial 49 (37.9%) and questions about ART intake 48 (37.2%), followed by other medical issues such as COVID-19 or body pains 9 (7.0%). Of 1,654 automated tuberculosis symptom calls triggered to participants, 31 (1.9%) were answered. Among these, 11 (35.5%) reported tuberculosis symptoms.

Conclusions

Automated SMS notifications to communicate viral load results and provide reminders for ART adherence and clinic visits encountered high uptake and were technically successful. However, uptake of other phone-based services was low, and technical challenges hindered the implementation of automated remote tuberculosis symptom screening calls.

Trial registration

ClinicalTrials.gov: NCT04527874 (registered 31 August 2020).